Ventricular tachyarrhythmias may occur during intravenous arsenic trioxide (As 2 O 3 ). This has not happened during oral As 2 O 3 . Sixteen patients were studied by electrocardiography and 24-hour Holter monitoring at baseline, during and after oral As 2 O 3 (As 2 O 3 -ON, As 2 O 3 -OFF). QT and corrected QT (QTc) were significantly longer during As 2 O 3 -ON than in As 2 O 3 -OFF, but QT and QTc dispersions were comparable. The patients' 24-hour heart rates were higher during As 2 O 3 -ON than in As 2 O 3 -OFF. QTc intervals at each hour were longer during As 2 O 3 -ON than in As 2 O 3 -OFF. However, QTc prolongation of more than 30 milliseconds only occurred at one time point (2 hours) after oral As 2 O 3 , resulting in QTc of more than 500 milliseconds in 3 of 16 patients, all within 4 hours of oral As 2 O 3 . Although the standard deviation of normal RR interval was lower during As 2 O 3 -ON, ratios of low frequency to high frequency power for As 2 O 3 -ON and As 2 O 3 -OFF were comparable. No ventricular proarrhythmias were observed. These observations, due to the lower peak plasma arsenic reached during oral 
Introduction
Arsenic trioxide (As 2 O 3 ) is efficacious in acute promyelocytic leukemia (APL). [1] [2] [3] [4] It blocks potassium currents I Kr and I Ks , 5 causing QT prolongation. Ventricular tachyarrhythmias were reported in about 30% of patients treated with intravenous As 2 O 3 . [6] [7] [8] [9] As 2 O 3 may be effective in other neoplasms, 10 making clinical trials of As 2 O 3 in these diseases pressing. However, reliance on intravenous As 2 O 3 hampers these efforts. Long-term intravenous As 2 O 3 is resource-demanding. Moreover, a potentially fatal cardiac toxicity is worrisome, especially in clinical trials.
We have developed an oral formulation of As 2 O 3 . 4, 11 Details of the preparation and pharmacokinetics of oral As 2 O 3 have been previously reported. 11 Oral As 2 O 3 gives a similar bioavailability, but lower peak plasma arsenic concentrations, as compared with intravenous As 2 O 3 . 11 Oral As 2 O 3 represents an advance in arsenic therapy. Patients take oral As 2 O 3 at home, rendering long-term therapy feasible, thus facilitating clinical trials. Most importantly, in more than 600 patient weeks of oral As 2 O 3 administered during 5 years, no ventricular tachyarrhythmias were observed. 4, 11 Prolongation of QT or corrected QT (QTc) increases the risks of ventricular tachyarrhythmias. 12, 13 QT-interval dispersion measures regional nonhomogeneities of ventricular repolarization. 14 Greater dispersions increase ventricular arrhythmias. 15 Heart rate variability (HRV) measures the beat-to-beat heart rate variations, correlating with changes in autonomic tone. HRV changes increase cardiac arrhythmias. 16 To explain the favorable cardiac side-effect profile of oral As 2 O 3 , we studied a cohort of patients on long-term oral As 2 O 3 , to determine the cardiac safety and changes of QT intervals and HVR.
Study design Patients
We studied 17 consecutive patients with relapsed APL (Table 1 ). All had normal left ventricular ejection fraction and blood biochemistry.
Study protocol
Patients received oral As 2 O 3 (10 mg/d) for 2 weeks, followed by a drug-free period of 6 to 8 weeks before the next course. Patients took oral As 2 O 3 at 14:00 every day to match the timing for electrocardiography (ECG) and Holter recording, and blood arsenic assay. Treatment protocol was approved by the institutional review board of Queen Mary Hospital, and all patients gave informed consent in accordance with the Declaration of Helsinki.
ECG and Holter measurement
Data were collected at day 10 of oral As 2 O 3 (As 2 O 3 -ON) and 4 weeks after stopping oral As 2 O 3 (As 2 O 3 -OFF). Resting 12-lead surface ECGs were recorded (paper-speed: 50 mm/second) for measuring QT intervals. QT intervals at each lead and the corresponding RR-interval at lead II were measured to calculate the QTc (Bazett formula: QTc ϭ QT/square-root of RR interval). QT dispersion was the difference between the maximum and minimal QT measured from each of 12 leads. During As 2 O 3 -ON and As 2 O 3 -OFF, 24-hour Holter monitoring (Zymed DigiTrak Plus; Zymed 1810, Philips, The Netherlands) was performed to assess circadian QT variations.
Data interpretation
Holter recordings were reviewed and edited manually. Recordings must exceed 20 hours and be of good quality to be analyzed. The time domain (standard deviation of normal RR interval [SDNN] ) and frequency domain (ratio of low-frequency to high-frequency power [LF/HF]) of HVR was measured to assess parasympathetic and sympathetic activities, respectively. 16 ECG and Holter were analyzed by a cardiologist blinded to patient treatment.
Elemental arsenic levels
After venepuncture, EDTA-anticoagulated blood was immediately separated into plasma and cell fractions. Arsenic levels were measured by inductively coupled plasma mass spectrometry. 17 
Statistical analysis
Continuous variables were expressed as mean plus or minus standard error of the mean. Comparisons were performed with the Student t test or Fisher exact test (SPSS software, version 10.0). P values less than .05 were considered significant.
Results and discussion

Patients and arsenic levels
Sixteen patients completed the study (one died of sepsis). Consistently, cellular arsenic levels were significantly higher than plasma arsenic ( Figure 1A ), similar to previous observations during long-term oral As 2 O 3 . 13 
ECG and Holter findings
Both QT and QTc were significantly longer during As 2 O 3 -ON than in As 2 O 3 -OFF (Table 2 , P Ͻ .01). However, the QT and QTc dispersion were comparable during As 2 O 3 -ON and As 2 O 3 -OFF (Table 2 , P Ͼ .05). Holter monitoring showed similar circadian heart rate variations during As 2 O 3 -ON and As 2 O 3 -OFF, but 24-hour heart rates were consistently higher during As 2 O 3 -ON than in As 2 O 3 -OFF, being significantly different during late evening (21: 00, 22:00, 23:00), early morning (02:00, 03:00, 04;00), and afternoon (12:00, 13:00, 14:00; P Ͻ .05; Figure 1B ).
QT measurements
QT intervals over 24 hours showed marked variations, although the pattern and measurement at each hour were comparable between As 2 O 3 -ON and As 2 O 3 -OFF ( Figure 1C ). Circadian variations of mean QTc intervals ( Figure 1D ) were comparable between As 2 O 3 -ON and As 2 O 3 -OFF, but measurements at each hour were significantly longer during As 2 O 3 -ON (P Ͻ .05, except at 06:00, 19:00, 23:00). The mean differences of QTc between As 2 O 3 -ON and As 2 O 3 -OFF are shown in Figure 1E . QTc prolongation of more than 30 milliseconds was observed at only one time point (16:00, 2 hours after oral As 2 O 3 ). No case had QTc prolongation of more than 50 milliseconds. This resulted in a QTc of more than 500 milliseconds in only 3 of 16 patients, all within 4 hours of oral As 2 O 3 . Although the SDNN was significantly lower during As 2 O 3 -ON than in As 2 O 3 -OFF, there was no significantly difference in LF/HF between As 2 O 3 -ON and As 2 O 3 -OFF (Table 2) .
Ventricular arrhythmias
Ventricular premature beats were comparably frequent between As 2 O 3 -ON and As 2 O 3 -OFF (0.03% Ϯ 0.02% versus 0.03% Ϯ 0.03%; P ϭ .8). No ventricular tachyarrhythmia was observed.
Conclusions and observations
Long-term oral As 2 O 3 significantly increased the mean heart rate and QTc interval, and reduced SDNN. However, QT-interval, QT and QTc dispersions, and LF/HF were not changed. Furthermore, for indicators of proarrhythmic risks, 12,13 significant QTc prolongation of more than 30 milliseconds was observed at only a single time point (2 hours after oral As 2 O 3 ), QTc prolongation never exceeded 50 milliseconds, and a QTc interval of more than 500 milliseconds was observed in only 3 patients within 4 hours of oral As 2 O 3 . Importantly, these observations translated into absent ventricular proarrhythmia in all patients. These results were superior to intravenous As 2 O 3 , where 26% of patients had QT intervals more than or equal to 500 milliseconds, with QTc interval prolonged by 30 to 60 milliseconds in 36.6% of treatment courses, and by more than 60 milliseconds in 35.4% of patients, resulting in torsades de pointes in 1% of cases. 8 The cardiac safety of oral As 2 O 3 may be due to several reasons. First, in ventricular proarrhythmias during intravenous As 2 O 3 , As 2 O 3 was infused over 1 to 3 hours. 6-9 Pharmacokinetic studies showed that peak plasma arsenic levels after intravenous As 2 O 3 reached 0.34 M to 2.0 M. 11 However, after oral As 2 O 3 , peak arsenic levels were much lower at 0.25 M to 0.55 M (although gradual intestinal absorption led to a total area-under-the-curve availability comparable to intravenous As 2 O 3 ). 11 Because of lower peak arsenic levels, QTc prolongations after oral As 2 O 3 were transient and lasted only 4 hours. Second, arsenic shows a concentration-dependent blockade of I Kr and I Ks currents (IC 50 , I Kr : 0.14 M Ϯ 0.01 M; I Ks : 1.13 M Ϯ 0.06 M). 5 Hence, peak plasma arsenic concentrations reached after intravenous As 2 O 3 , but not oral As 2 O 3 , are high enough to block I Kr and I Ks , thereby severely compromising repolarization and increasing susceptibility to ventricular proarrhythmias.
Finally, heart rates were significantly increased during oral As 2 O 3 . HVR analysis demonstrated significant decreases in parasympathetic activity without changes in sympathetic activity. The change in sympathetic/parasympathetic balance increases the heart rate, alleviating risks of ventricular tachyarrhythmias during QT prolongation. Hence, despite significant increases in QTc interval, overall QT intervals were unchanged during oral As 2 O 3 .
A limitation of this study is absence of an intravenous As 2 O 3 control group. Since formulation of oral As 2 O 3 in 2000, we have not used intravenous As 2 O 3 , making it difficult to include an intravenous As 2 O 3 group just for this study. Previous reports of intravenous As 2 O 3 have not measured QT dispersion, HRV, and circadian QT and HR variations, so how they relate to arrhythmias during intravenous As 2 O 3 is difficult to judge. Finally, a 1% frequency of torsades de pointes in intravenous As 2 O 3 might not have been detected in our study size.
Our results provide insights into how an oral formulation improves the cardiac safety of As 2 O 3 . Oral As 2 O 3 is convenient and safe for outpatients, and may be the preferred formulation for prolonged arsenic treatment. 
